{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:06Z","timestamp":1790732946690,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases of the US National Institutes of Health","award":["R03AI180576"],"award-info":[{"award-number":["R03AI180576"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) infection is associated with unfavorable multidrug- and rifampicin-resistant (MDR\/RR) tuberculosis (TB) outcomes. We examined whether this association would decrease in settings where no participants were lost-to-follow-up or where all adhered to regimens comprised of priority TB drugs. We analyzed data from 1,530 participants with HCV testing in the endTB observational cohort (NCT03259269). We estimated the relative risk of death, treatment failure, and loss-to-follow-up comparing participants with and without HCV, using inverse probability weighting to adjust for confounding. We then estimated relative risks of HCV on death and failure in weighted pseudopopulations representing hypothetical interventions eliminating loss-to-follow-up and ensuring adherence to strong MDR\/RR-TB regimens. The unadjusted risk difference comparing participants with and without HCV was 14.1% (95% confidence interval [CI], 8.0%-20.1%), decreasing to 11.0% (95% CI, 3.0%-19.1%) after weighting. In pseudopopulations without loss-to-follow-up or with adequate adherence to strong regimens, the risk differences were 7.7% (95% CI, 0.8%-16.2%) and 7.0% (95% CI,\u22121.6% to 17.3%), respectively. Adjustment for baseline confounders attenuated the association between HCV and unfavorable outcomes, suggesting these factors partly explain the disparity. Further attenuation after eliminating loss-to-follow-up suggests that improving treatment retention in MDR\/RR-TB care may reduce outcome disparities among patients with HCV.<\/jats:p>","DOI":"10.1093\/aje\/kwag024","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:43:36Z","timestamp":1769863416000},"page":"1615-1623","source":"Crossref","is-referenced-by-count":1,"title":["Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-133X","authenticated-orcid":false,"given":"Allison","family":"LaHood","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA 02115 ,","place":["United States"]},{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-209X","authenticated-orcid":false,"given":"James","family":"Robins","sequence":"additional","affiliation":[{"name":"CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4022-3447","authenticated-orcid":false,"given":"Helen R","family":"Stagg","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine , London WC1E 7HT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6754-4182","authenticated-orcid":false,"given":"Sara","family":"Sauer","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Interactive Research and Development (IRD) , Karachi 75190 ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Bastard","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, Epicentre , Paris 75019 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-9635","authenticated-orcid":false,"given":"Lorenzo","family":"Guglielmetti","sequence":"additional","affiliation":[{"name":"Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital , Negrar di Valpolicella, Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-1479","authenticated-orcid":false,"given":"Catherine","family":"Hewison","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Paris 75019 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-9063","authenticated-orcid":false,"given":"Helena","family":"Huerga","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, Epicentre , Paris 75019 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshan K","family":"Isani","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Directorate General Health Services , Sindh ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-8355","authenticated-orcid":false,"given":"Palwasha","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research and Development (IRD) Global , 048581 ,","place":["Singapore"]},{"name":"Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine , London WC1E 7HT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3602-5950","authenticated-orcid":false,"given":"Uzma","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University , Montreal, QC H3A 1A2 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8064-1956","authenticated-orcid":false,"given":"Nino","family":"Lomtadze","sequence":"additional","affiliation":[{"name":"The National Center for Tuberculosis and Lung Diseases , Tbilisi 0101 ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Mamsa","sequence":"additional","affiliation":[{"name":"Indus Hospital & Health Network (IHHN), Karachi 75190 ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nara","family":"Melikyan","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, Epicentre , Paris 75019 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-658X","authenticated-orcid":false,"given":"Carole D","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]},{"name":"Partners In Health , Boston, MA 02199 ,","place":["United States"]},{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"Rich","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]},{"name":"Partners In Health , Boston, MA 02199 ,","place":["United States"]},{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-4625","authenticated-orcid":false,"given":"Kwonjun","family":"Seung","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]},{"name":"Partners In Health , Boston, MA 02199 ,","place":["United States"]},{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Rafi","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Institute of Chest Diseases (ICD) , Kotri 76040, Sindh ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-0272","authenticated-orcid":false,"given":"Alena","family":"Skrahina","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center of Pulmonology and Tuberculosis , 220053 Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assel","family":"Stambekova","sequence":"additional","affiliation":[{"name":"Partners In Health , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girum B","family":"Tefera","sequence":"additional","affiliation":[{"name":"Partners In Health , Freetown ,","place":["Sierra Leone"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-5728","authenticated-orcid":false,"given":"Molly F","family":"Franke","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA 02115 ,","place":["United States"]},{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026060322204938300_ref1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/CLEP.S43926","article-title":"Socioeconomic status in HCV infected patients\u2014risk and prognosis","volume":"5","author":"Omland","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"4 Suppl 3","key":"2026060322204938300_ref2","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19501","article-title":"Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia","volume":"17","author":"Kazatchkine","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"2026060322204938300_ref3","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"3","key":"2026060322204938300_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.101596","article-title":"Epidemiology of hepatitis C virus infection","volume":"45","author":"Roudot-Thoraval","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"2026060322204938300_ref5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcma.2017.10.002","article-title":"The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis","volume":"81","author":"Chang","year":"2018","journal-title":"J Chin Med Assoc"},{"issue":"6","key":"2026060322204938300_ref6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.5588\/ijtld.15.0668","article-title":"Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis","volume":"20","author":"Lee","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"2026060322204938300_ref7","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1017\/S0950268814002970","article-title":"Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000\u20132010","volume":"143","author":"Bushnell","year":"2015","journal-title":"Epidemiol Infect"},{"key":"2026060322204938300_ref8","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","author":"Hoofnagle","year":"2012"},{"issue":"2","key":"2026060322204938300_ref9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0002-9343(96)00402-0","article-title":"Nonadherence in tuberculosis treatment: predictors and consequences in New York City","volume":"102","author":"Pablos-M\u00e9ndez","year":"1997","journal-title":"Am J Med"},{"issue":"6","key":"2026060322204938300_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab190","article-title":"Understanding nonadherence to tuberculosis medications in India using urine drug metabolite testing: a cohort study. Open forum","volume":"8","author":"Subbaraman","year":"2021","journal-title":"Infect Dis"},{"issue":"3","key":"2026060322204938300_ref11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5588\/pha.21.0007","article-title":"Risk factors for poor engagement in drug-resistant TB care in South Africa: a systematic review","volume":"11","author":"McNabb","year":"2021","journal-title":"Public Health Action"},{"issue":"1","key":"2026060322204938300_ref12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12889-022-12879-6","article-title":"Inadequate housing and pulmonary tuberculosis: a systematic review","volume":"22","author":"Lee","year":"2022","journal-title":"BMC Public Health"},{"issue":"1","key":"2026060322204938300_ref13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijtb.2017.05.003","article-title":"Social support a key factor for adherence to multidrug-resistant tuberculosis treatment","volume":"65","author":"Deshmukh","year":"2018","journal-title":"Indian J Tuberc"},{"issue":"8","key":"2026060322204938300_ref14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.5588\/ijtld.11.0713","article-title":"Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care","volume":"16","author":"Brust","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"2026060322204938300_ref15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3201\/eid1209.051618","article-title":"Multidrug-resistant tuberculosis management in resource-limited settings","volume":"12","author":"Nathanson","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2026060322204938300_ref16","volume-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance [Internet]","author":"World Health Organization","year":"2013"},{"key":"2026060322204938300_ref17","volume-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance [Internet]","author":"World Health Organization","year":"2016"},{"key":"2026060322204938300_ref18","article-title":"endTB clinical and programmatic guide for patient management with new TB drugs. Version 4.0 [Internet]","year":"2018","journal-title":"endTB Consortium"},{"issue":"1","key":"2026060322204938300_ref19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1186\/s12879-019-4378-4","article-title":"The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026060322204938300_ref20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13063-024-07999-w","article-title":"Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial","volume":"25","author":"Weir","year":"2024","journal-title":"Trials"},{"key":"2026060322204938300_ref21","volume-title":"Module 4: treatment - drug-resistant tuberculosis treatment, 2022","author":"World Health Organization","year":"2022"},{"issue":"6","key":"2026060322204938300_ref22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5588\/ijtld.22.0613","article-title":"Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications","volume":"27","author":"Rich","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10150","key":"2026060322204938300_ref23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet."},{"issue":"25","key":"2026060322204938300_ref24","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2026060322204938300_ref25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1164\/rccm.202211-2125OC","article-title":"Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis","volume":"207","author":"Trevisi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2026060322204938300_ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000818","article-title":"Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective","volume":"3","author":"Rodriguez","year":"2023","journal-title":"PLOS Glob Public Health"},{"issue":"5","key":"2026060322204938300_ref27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5588\/ijtldopen.24.0515","article-title":"Effectiveness of a bedaquiline, linezolid, clofazimine \u201ccore\u201d for multidrug-resistant TB","volume":"2","author":"Zeng","year":"2025","journal-title":"IJTLD Open."},{"key":"2026060322204938300_ref28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101938","article-title":"Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis","volume":"58","author":"Olaru","year":"2023","journal-title":"eClinicalMedicine."},{"issue":"6","key":"2026060322204938300_ref29","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1053\/j.gastro.2008.02.069","article-title":"Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors","volume":"134","author":"Missiha","year":"2008","journal-title":"Gastroenterology."},{"issue":"9055","key":"2026060322204938300_ref30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet."},{"issue":"10","key":"2026060322204938300_ref31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","article-title":"Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis","volume":"26","author":"Smith","year":"2015","journal-title":"Int J Drug Policy"},{"issue":"6","key":"2026060322204938300_ref32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"2026060322204938300_ref33","doi-asserted-by":"publisher","first-page":"e01215","DOI":"10.1128\/AAC.01215-19","article-title":"A pharmacology perspective on simultaneous tuberculosis and hepatitis C treatment","volume":"63","author":"Kempker","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2026060322204938300_ref34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa653","article-title":"Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe. Open forum","volume":"8","author":"Melikyan","year":"2021","journal-title":"Infect Dis"},{"issue":"6","key":"2026060322204938300_ref35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jinf.2022.03.004","article-title":"Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study","volume":"84","author":"Tunesi","year":"2022","journal-title":"J Infect"},{"key":"2026060322204938300_ref36","doi-asserted-by":"crossref","DOI":"10.2471\/B09017","volume-title":"Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: Rapid Communication","author":"World Health Organization","year":"2024"},{"key":"2026060322204938300_ref37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2458-14-46","article-title":"The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies","volume":"14","author":"Baral","year":"2014","journal-title":"BMC Public Health"},{"issue":"3","key":"2026060322204938300_ref38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jcv.2014.04.001","article-title":"Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations","volume":"60","author":"Paula Scalioni","year":"2014","journal-title":"J Clin Virol"},{"issue":"1","key":"2026060322204938300_ref39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cid\/ciad589","article-title":"Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without human immunodeficiency virus: the impact of assumptions about death and missing follow-up","volume":"78","author":"Sauer","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2026060322204938300_ref40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwag024\/66706182\/kwag024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/6\/1615\/66706182\/kwag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/6\/1615\/66706182\/kwag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:20:54Z","timestamp":1780539654000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/195\/6\/1615\/8454588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwag024","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,2]]}}}